HamiltonRG. Monoclonal antibodies in the diagnosis and treatment of human disease. Ann Biol Clin Paris1989;47:575–81.
2.
MoiMKDe NardoSJMearesCF. Stable bifunctional chelates of metals used in radiotherapy. Cancer Res1990;50:789s–93s.
3.
JansenFKBlythmanHECarriereD. Immunotoxins: Hybrid molecules combing high specificity and protein cytotoxicity. Immunol Rev1982;62:185.
4.
JonesDHGoldmanAGordonI. Therapeutic application of a radiolabeled monoclonal antibody in nude mice xenografted with human neuroblastoma: Tumoricidal effects and distribution studies. Int J Cancer1985;35:715–20.
5.
ColcherDKeenanAMLarsonSM. Prolonged binding of radiolabeled monoclonal antibody (B72.3) used for the in-situ radioimmunodetection of human colon cancer xenografts. Cancer Res1984;44:5744–51.
6.
EstebanJMColcherDSugarbakerP. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MoAb B72.3. Int J Cancer1987;39:50–9.
7.
HummJLGladstoneDJBelleriveMR. Dosimetry of radiolabeled antibodies. In: EpeneosAA, ed. Monoclonal antibodies: applications in clinical oncology. London: Chapman and Hall Medical, 1991:79–86.
8.
JainRK. Transport of molecules across tumour vasculature. Cancer Metastasis Rev1987;6:559–94.
9.
JainRK. Tumour physiology and antibody delivery. In: VaethJMMeyerJL, eds. The present and future role of monoclonal antibodies in the management of cancer. Front Radiat Ther Oncol, vol 24. Basel: Karger, 1990:32–46.
10.
ZalutskyMRNoskaMAGolapintoEV. Enhanced tumour localisation and in-vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(Tri-n-butylstannyl)benzoate. Cancer Res1989;49:5543–9.
11.
LashfordLSHancockJPKemsheadJT. mIBG uptake and storage in the human neuroblastoma cell line SK-N-BE(2C). Int J Cancer1991;47:105–9.
12.
ShapiroBCoppJESissonJC. 131I-mIBG for the locating of suspected phaeochromocytomas: Experience in 400 cases. J Nucl Med1985;26:576–85.
13.
LewisILashfordLSFieldingSFlowerMAckeryDKemsheadJT. A Phase I/II study of 131I-mIBG in chemoresistant neuroblastoma. In: EvansEA, ed. Advances in Neuroblastoma Research. New York: Wiley-Liss Inc., 1991:463–9.
14.
LeeYSBullardDEWikstrandCJ. Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. Cancer Res1987;47:1941–6.
15.
KemsheadJTJonesDLashfordLS. 131I coupled to monoclonal antibodies as therapeutic agents for neuroectodermally derived tumours: Fact or fiction?Cancer Drug Del1986;3:25–43.
16.
HertlerAAFrankelAE. Immunotoxins: A clinical review of their use in the treatment of malignancies. J Clin Oncol1989;7:1932–42.
17.
EngertAMartinGAmlotP. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A chain have potent anti-tumour effects against human Hodgkin cells in-vitro and solid Hodgkin tumours in mice. Int J Cancer1991;49:450–6.
18.
De NardoSJDe NardoGLO'GradyLF. Pilot studies of radioimmunotherapy of B-cell lymphoma and leukaemia using 131I Lym-1 monoclonal antibody. Antibody, Immunoconj Radiopharm1988;1:17–33.
19.
PressOWEaryJFBadgerCC. High-dose radioimmunotherapy of B-cell lymphomas. In: VaethJMMeyerJL, eds. The present and future role of monoclonal antibodies in the management of cancer. Front Radiat Ther Oncol. Basel: Karger, 1990:204–13.
20.
DillmanROShawlerDLCollinesHA. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukaemia. Blood1982;59:1036–45.
21.
StewartJSHirdVSnookD. Intraperitoneal 131I and 90Y labelled monoclonal antibodies for ovarian cancer: Pharmacokinetics and normal tissue dosimetry. Int J Cancer1988;3(Suppl):71–6.
22.
EpenetosAACourtenay-LuckNSnookSJ. Antibody guided irradiation of advanced ovarian carcinoma with intra-peritoneally administered radiolabelled monoclonal antibodies. J Clin Oncol1987;12:1890–9.
23.
HirdVStewartJSSnookD. Intraperitoneally administered 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1–2 trial: Problems encountered and possible solutions. Br J Cancer1990;62:48–51.
24.
MoseleyRPDaviesAGRichardsonRB. Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer1990;62:637–42.
25.
PizerBPapanastassiouVHancockJ. A pilot study of monoclonal targeted radiotherapy in the treatment of central nervous system leukaemia in children. Br J Haem1991;77:466–72.
26.
MoseleyRPZalutskyMREvansS. Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer1992 (In press).
27.
BradyLWMarkoeAMWooDV. 125I-labelled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. In: VaethJMMeyerJL, eds. The present and future role of monoclonal antibodies in the management of Cancer. Front Radiat Ther Oncol. Basel: Karger, 1990:151–60.
28.
BradyLWMarkoeAMWooDV. 125I labelled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas: A pilot study. J Neurosurg Sci1990;34:243–9.
